pharmanewsdaily

Sumitomo Dainippon Pharma has signed a deal worth $3 billion to assume ownership of stakes held by Roivant Sciences in certain biopharma companies (Vants), as per the latest pharma acquisition news. The deal will help in creating a biopharma alliance between the two companies. As per the terms of the deal, the Japanese pharma company […]

The post Sumitomo Dainippon Pharma to buy into Roivant Sciences Vants for $3bn appeared first on PharmaNewsDaily.com.

US biotech company Puma Biotechnology has secured orphan drug designation to NERLYNX (neratinib) from the US Food and Drug Administration (FDA) for the treatment of breast cancer patients having brain metastases, as per the latest pharma regulatory news. The FDA orphan drug designation program is given to investigational drugs designed for the treatment, prevention, or […]

The post Puma secures FDA orphan drug status for NERLYNX in breast cancer with brain metastases appeared first on PharmaNewsDaily.com.

German pharma company Fresenius Kabi has launched the Phenylephrine Hydrochloride Injection, USP in the US, which is an alpha-1 adrenergic receptor agonist indicated for raising blood pressure in adults with clinically important hypotension caused mainly from vasodilation, in such settings as anesthesia or septic shock. Fresenius Kabi Phenylephrine Hydrochloride Injection, USP has been rolled out […]

The post Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US appeared first on PharmaNewsDaily.com.

Valo Therapeutics (Valo Tx) has licensed proprietary PeptiENV technology from Helsinki University that is designed to facilitate the coating of enveloped viruses with antigens associated with tumour. The Finnish immuno-oncology company, which is a spin-out company from the Finland-based University of Helsinki, is focused on developing tumour antigen-coated oncolytic viruses as therapeutic vaccines. Previously, Valo […]

The post Valo Therapeutics licenses PeptiENV technology from the University of Helsinki appeared first on PharmaNewsDaily.com.

ARUP Laboratories and Techcyte have joined forces to develop a new digital diagnostics platform in the form of an artificial intelligence-augmented (AI-augmented) ova and parasite detection tool. While ARUP Laboratories is a US-based national reference laboratory, Techcyte provides image analysis solutions powered by AI technology. According to the reference laboratory, by digitally enabling the workflow, […]

The post ARUP, Techcyte join forces for AI-augmented ova and parasite detection tool appeared first on PharmaNewsDaily.com.

Health technology company Royal Philips has launched HeartStart Intrepid monitor/defibrillator with IntelliSpace Connect in Europe and certain markets in Asia and Africa. The HeartStart Intrepid with IntelliSpace Connect has been designed to help caregivers in assessing and treating patients during medical emergencies in pre-hospital and hospital settings alike. The monitor cum defibrillator device is CE […]

The post Royal Philips launches HeartStart Intrepid with IntelliSpace Connect appeared first on PharmaNewsDaily.com.

Boston Scientific acquisition of BTG : US medical devices manufacturer Boston Scientific has wrapped up its previously announced $4.2 billion acquisition of UK-based healthcare company BTG. In November 2018, Boston Scientific reached an agreement on the terms of a recommended offer to acquire the British healthcare company for a cash consideration of 840 pence per […]

The post Boston Scientific wraps up $4.2bn acquisition of BTG appeared first on PharmaNewsDaily.com.

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

The post MERU clinical trial : AbbVie ends Rova-T program in lung cancer appeared first on PharmaNewsDaily.com.

Surmodics has wrapped up enrollment for the TRANSCEND clinical trial for the SurVeil drug-coated balloon (SurVeil DCB) for the treatment of peripheral artery disease (PAD) in the upper leg. Based in Minnesota, Surmodics is a provider of medical device and in vitro diagnostic technologies to the health care industry. The TRANSCEND clinical trial has enrolled […]

The post Surmodics wraps up enrollment for TRANSCEND trial of SurVeil DCB appeared first on PharmaNewsDaily.com.